STYLAGE® S BI-FLEX® with Lidocaine

Description

Name: STYLAGE® S BI-FLEX® with Lidocaine
Manufacturer: Vivacy
Active Substance(s): CROSS-LINKED HYALURONIC ACID (HA), MANNITOL, LIDOCAINE
Strength: 16mg/g HA, 3mg/ml Lidocaine, 9mg/ml Mannitol
Package Content: 2 x 0.8ml Pre-Filled Syringes, 4 x 30 G ½ Needles

STYLAGE® S BI-FLEX® with Lidocaine is an injectable hyaluronic acid dermal filler developed by Laboratories VIVACY, France, for the correction of fine lines, superficial wrinkles, and skin texture irregularities. Formulated with 16mg/g cross-linked hyaluronic acid, 9mg/mL mannitol, and 3mg/mL lidocaine, it combines IPN-Like Technology™ with a patented syringe system rebranded from Bi-SOFT® for improved ergonomics, injection precision, and safety. Supplied as 2 × 0.8mL prefilled syringes with 4 × 30G ½ needles, practitioners seeking to buy STYLAGE® S BI-FLEX® with Lidocaine online may contact Maylips support team for guidance.

• Strength: 16mg/g HA | 9mg/mL Mannitol | 3mg/mL Lidocaine
• Active Ingredient: Hyaluronic acid (cross-linked) 16mg/g; Mannitol 9mg/mL; Lidocaine 3mg/mL
• Dosage Form: Injectable gel — 2 × 0.8mL prefilled syringes (BI-FLEX® syringe system, rebranded from Bi-SOFT®) + 4 × 30G ½ needles
• FDA Approval Date: STYLAGE® is NOT FDA-approved for U.S. use. The product carries CE marking for European Union markets only (CE certification for medical devices under the EU MDR).
• Molecular Type: Cross-linked hyaluronic acid (IPN-Like Technology™) with mannitol and lidocaine
• Intended Use: Fine line correction, superficial wrinkle treatment, skin texture refinement — for licensed aesthetic professionals
• Brand: STYLAGE®
• Country of Origin: France
• Manufacturer: Laboratories VIVACY (Paris, France)

Among the STYLAGE® product line, STYLAGE® S BI-FLEX® with Lidocaine is engineered specifically for superficial dermal correction rather than deep volumization.

• Targeted Concentration: It features a 16 mg/g hyaluronic acid (HA) concentration, lower than STYLAGE® M and L, tailored for precise, shallow integration in delicate treatment areas.
• IPN-Like Technology™: This proprietary method interlocks two distinct HA polymer networks. It optimizes cohesivity, elasticity, and tissue integration to ensure natural-looking results in the superficial dermis.

Ergo-Precision Delivery System

The product incorporates a patented syringe system designed to complement its unique rheological profile, supporting consistent, controlled extrusion in superficial treatment planes. This delivery hardware offers several clinical advantages over its predecessor:

• Enhanced practitioner control
• Improved injection precision
• Superior ergonomics

Longevity & Patient Comfort

• Oxidative Protection: Formulated with 9 mg/mL mannitol, a potent free radical scavenger. Mannitol helps shield the HA matrix from immediate oxidative degradation, which may extend product longevity.
• Variable Duration: Individual clinical persistence varies based on patient-specific factors, including skin type, lifestyle, and the precise anatomical treatment area.

Integrated Pain Management: The co-formulation of 3 mg/mL lidocaine modulates pain signaling, significantly improving patient comfort during superficial injections without requiring a separate local anesthetic step.

STYLAGE® S BI-FLEX® with Lidocaine is intended for licensed aesthetic professionals seeking a superficial-plane filler for delicate correction and skin refinement. Common indications include:

• Fine line correction in periorbital and perioral areas
• Superficial wrinkle treatment, including the superficial component of nasolabial folds and marionette lines
• Glabellar line treatment
• Correction of superficial skin texture irregularities

Because this formulation is specifically designed for superficial dermal placement, it is not indicated for significant volume restoration or deep wrinkle correction. For deeper folds, advanced volume loss, or structural contouring, practitioners should consider STYLAGE® M or STYLAGE® L formulations, which are better suited for deeper injection planes. Patient selection should account for the condition of the patient’s skin, treatment goals, skin type, and intended treatment area.

Cross-linked hyaluronic acid integrates into the superficial dermis and binds water molecules, producing an immediate hydrating and fine line smoothing effect. IPN-Like Technology™ enhances cohesivity and elasticity through interlocked polymer networks that maintain structural integrity in the superficial plane while supporting natural facial movement.

Mannitol provides additional stability by scavenging free radicals that promote oxidative hyaluronic acid degradation, potentially extending product longevity beyond standard HA formulations. The co-formulated lidocaine (3mg/mL) modulates pain signaling during injection, improving comfort in delicate superficial areas without requiring a separate anesthetic procedure.

STYLAGE® S BI-FLEX® with Lidocaine is fully reversible through hyaluronidase administration if correction adjustment or removal is required.

STYLAGE® S BI-FLEX® with Lidocaine injection is designed for placement within the superficial dermis using an intradermal technique, and should only be performed by trained medical professionals experienced in facial anatomy and injectable procedures. Following treatment, patients should avoid excessive sun exposure until redness and swelling resolve. Bruising at the injection site may occur and typically resolves within a few days.

Common Side Effects

Common post-treatment reactions include redness, swelling, tenderness, bruising at the injection site, and mild discomfort. These reactions are generally transient and localized, typically resolving within a few days, though recovery may vary depending on the treatment area and factors such as skin type.

Serious Adverse Events

Although rare, serious complications may occur with all injectable dermal fillers, including vascular occlusion, tissue ischemia, skin necrosis, infection, and hypersensitivity reactions. Practitioners should be prepared to manage vascular complications and maintain familiarity with hyaluronidase protocols. Patients with known hypersensitivity to hyaluronic acid or amide-type anesthetics should be carefully evaluated before treatment. Refer to the complete IFU for comprehensive safety information.

STYLAGE® S BI-FLEX® with Lidocaine is manufactured in France by Laboratories VIVACY and is CE-marked for professional aesthetic use within applicable European markets. Current U.S. FDA regulatory status and regional requirements should be independently verified before procurement or clinical use. Practitioners evaluating sourcing options should confirm distributor authenticity, cold-chain compliance, and applicable regional regulations when buying online. Practitioners who wish to buy dermal fillers or buy STYLAGE® products may contact Maylips support team for sourcing information and documentation support.

For sourcing guidance, contact Maylips support team.

Regulatory information current as of mid 2026. Practitioners should confirm local regulatory status before sourcing.